A paradigm for peptide vaccine delivery using viral epitopes encapsulated in degradable polymer hydrogel capsules

Biomaterials ◽  
2009 ◽  
Vol 30 (28) ◽  
pp. 5178-5186 ◽  
Author(s):  
Siow-Feng Chong ◽  
Amy Sexton ◽  
Robert De Rose ◽  
Stephen J. Kent ◽  
Alexander N. Zelikin ◽  
...  
ACS Nano ◽  
2009 ◽  
Vol 3 (11) ◽  
pp. 3391-3400 ◽  
Author(s):  
Amy Sexton ◽  
Paul G. Whitney ◽  
Siow-Feng Chong ◽  
Alexander N. Zelikin ◽  
Angus P. R. Johnston ◽  
...  

ACS Nano ◽  
2012 ◽  
Vol 6 (2) ◽  
pp. 1463-1472 ◽  
Author(s):  
Olga Shimoni ◽  
Almar Postma ◽  
Yan Yan ◽  
Andrew M. Scott ◽  
Joan K. Heath ◽  
...  

ACS Nano ◽  
2010 ◽  
Vol 4 (5) ◽  
pp. 2928-2936 ◽  
Author(s):  
Yan Yan ◽  
Angus P. R. Johnston ◽  
Sarah J. Dodds ◽  
Marloes M. J. Kamphuis ◽  
Charles Ferguson ◽  
...  

Small ◽  
2010 ◽  
Vol 6 (14) ◽  
pp. 1558-1564 ◽  
Author(s):  
Olga Kulygin ◽  
Andrew D. Price ◽  
Siow-Feng Chong ◽  
Brigitte Städler ◽  
Alexander N. Zelikin ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Weiteng An ◽  
Sira Defaus ◽  
David Andreu ◽  
Pilar Rivera-Gil

Mesoporous silica nanoparticles have drawn increasing attention as promising candidates in vaccine delivery. Previous studies evaluating silica-based vaccine delivery systems concentrated largely on macromolecular antigens, such as inactivated whole viruses. In this study, we synthesized dendritic mesoporous silica nanoparticles (DMSNs), and we evaluated their effectiveness as delivery platforms for peptide-based subunit vaccines. We encapsulated and tested in vivo an earlier reported foot-and-mouth disease virus (FMDV) peptide vaccine (B2T). The B2T@DMSNs formulation contained the peptide vaccine and the DMSNs without further need of other compounds neither adjuvants nor emulsions. We measured in vitro a sustained release up to 930 h. B2T@DMSNs-57 and B2T@DMSNs-156 released 23.7% (135 µg) and 22.8% (132 µg) of the total B2T. The formation of a corona of serum proteins around the DMSNs increased the B2T release up to 61% (348 µg/mg) and 80% (464 µg/mg) for B2T@DMSNs-57 and B2T@DMSNs-156. In vitro results point out to a longer sustained release, assisted by the formation of a protein corona around DMSNs, compared to the reference formulation (i.e., B2T emulsified in Montanide). We further confirmed in vivo immunogenicity of B2T@DMSNs in a particle size-dependent manner. Since B2T@DMSNs elicited specific immune responses in mice with high IgG production like the reference B2T@Montanide™, self-adjuvant properties of the DMSNs could be ascribed. Our results display DMSNs as efficacious nanocarriers for peptide-based vaccine administration.


2020 ◽  
Vol 27 (17) ◽  
pp. 2887-2901 ◽  
Author(s):  
Stacey Bartlett ◽  
Mariusz Skwarczynski ◽  
Istvan Toth

Background: Innate immune system plays an important role in pathogen detection and the recognition of vaccines, mainly through pattern recognition receptors (PRRs) that identify pathogen components (danger signals). One of the typically recognised bacterial components are lipids in conjugation with peptides, proteins and saccharides. Lipidic compounds are readily recognised by the immune system, and thus are ideal candidates for peptide- based vaccine delivery. Thus, bacterial or synthetic lipids mixed with, or conjugated to, antigens have shown adjuvant properties. These systems have many advantages over traditional adjuvants, including low toxicity and good efficacy for stimulating mucosal and systemic immune responses. Methods: The most recent literature on the role of lipids in stimulation of immune responses was selected for this review. The vast majority of reviewed papers were published in the last decade. Older but significant findings are also cited. Results: This review focuses on the development of lipopeptide vaccine systems including application of palmitic acid, bacterial lipopeptides, glycolipids and the lipid core peptide and their routes of administration. The use of liposomes as a delivery system that incorporates lipopeptides is discussed. The review also includes a brief description of immune system in relation to vaccinology and discussion on vaccine delivery routes. Conclusion: Lipids and their conjugates are an ideal frontrunner in the development of safe and efficient vaccines for different immunisation routes.


Small ◽  
2010 ◽  
Vol 6 (20) ◽  
pp. 2201-2207 ◽  
Author(s):  
Alexander N. Zelikin ◽  
Andrew D. Price ◽  
Brigitte Städler

2010 ◽  
Vol 11 (8) ◽  
pp. 2123-2129 ◽  
Author(s):  
Alexander N. Zelikin ◽  
Kerry Breheney ◽  
Remy Robert ◽  
Elvira Tjipto ◽  
Kim Wark

Nanoscale ◽  
2009 ◽  
Vol 1 (1) ◽  
pp. 68 ◽  
Author(s):  
Brigitte Städler ◽  
Andrew D. Price ◽  
Rona Chandrawati ◽  
Leticia Hosta-Rigau ◽  
Alexander N. Zelikin ◽  
...  

Langmuir ◽  
2011 ◽  
Vol 27 (5) ◽  
pp. 1724-1730 ◽  
Author(s):  
Siow-Feng Chong ◽  
Ji Hyun Lee ◽  
Alexander N. Zelikin ◽  
Frank Caruso

Sign in / Sign up

Export Citation Format

Share Document